Open AccessPersistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma
Author(s) -
Sposato Bruno,
Scalese Marco,
Ricci Alberto,
Rogliani Paola,
Paggiaro Pierluigi
Publication year - 2021
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13325
Subject(s) - medicine , bronchodilator , salbutamol , asthma , airway obstruction , eosinophil , persistence (discontinuity) , airway , lung function , bronchodilator agents , gastroenterology , anesthesia , cardiology , lung , geotechnical engineering , engineering
Objective This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods About 202 severe asthmatics were studied after 12–120 months of step‐5 treatment associated to anti‐IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV 1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results Pre‐/post‐treatment bronchodilator FEV 1 % and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), whereas BE were higher (380 cells/µl [170–590]) in RAO+ compared to RAO− subjects (77% [64–88], p = 0.0001, 81.8% [66.1–94.3], p = 0.0001, 21[18–23], p = 0.045 and 230 cells/µl [80–360], p = 0.003). A negative relationship between SABA‐induced FEV 1 % changes and pre‐bronchodilator FEV 1 % ( β = −0.551%; p = 0.0001) and ACT ( β = −0.059; p = 0.038) was found. Conversely, post‐treatment BE levels were positively related ( β = 145.565 cells/µl; p = 0.003) to FEV 1 > 12% increases. A rising trend of pre‐/post‐bronchodilator FEV 1 % in time was observed in RAO− subjects with BE < 300 cells/µl. Conversely, we highlighted significant declining tendencies of pre/post‐bronchodilator FEV 1 % in RAO+ patients with BE > 300 cells/µl reaching lower values after more than 36 months of step‐5 treatment (59.6% [39.9–72.1] vs 74[66.5–89.2] of RAO+ individuals with BE < 300 cells/µl [ p = 0.026] and 81.6% [66.1–91.8] of RAO‐subjects with BE > 300 cells/µl [ p = 0.009]). Conclusion Persistent SABA‐induced FEV 1 > 12%, especially when associated to BE > 300 cells/ml, may be a marker of accelerated lung function decline in severe asthmatics despite maximal step‐5 treatment. The highest bronchodilation associated to the lowest BE levels should be the main goal of asthma treatment to prevent such decline.